Host treatments affecting artificial pulmonary metastases: interpretation of loss of radioactively labelled cells from lungs.
The effect has been examined of various host treatments (C. parvum injection, immunization, thoracic irradiation, cyclophosphamide injection, and anticoagulation) on both lung colony formation and clearance of radioactive cells from the lungs after i.v. injection of tumour cells. Two tumour-host models have been used: the non-immunogenic KHT tumour in C3H/Km mice, and the immunogenic EMT6 tumour in BALB/c/Ka mice. Even for the at most weakly immunogenic KHT tumour, the number of artificial pulmonary metastases could be modified by a factor of up to 10(4) by different host treatments before i.v. inoculation of tumour cells. For all pretreatments except immunization, the shape of the curve of loss of radioactivity from the lungs vs time was biphasic, with an initial steep portion representing intravascular death of the tumor cells, followed 1--2 days after tumour-cell injection by a shallow exponential curve. It was concluded that the shallow slope represented spontaneous death of tumour cells in the perivascular tissues. Essentially all the injected tumour cells lodged initially in the lungs, and this was unaffected by the different host treatments. Furthermore, except for specific immunization, cell death in the perivascular tissues was also unaffected by host treatment. However, the survival of the tumour cells during the 24 h after injection (before they became extravascular) was extremely dependent on the particular host pretreatment. It would appear from these studies that host treatments such as C. parvum injection or anticoagulation can markedly affect the number of blood-borne pulmonary metastases, but they will only be effective if given before the tumor cells arrive in the lung vasculature.
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D002470:Cell Survival / Q000528:radiation effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000097:blood / Q000517:prevention & control / Q000556:secondary*; D008325:Mammary Neoplasms, Experimental / Q000556:secondary; D051379:Mice; D008815:Mice, Inbred Strains; D009360:Neoplastic Cells, Circulating; D011425:Propionibacterium acnes / Q000276:immunology; D012513:Sarcoma, Experimental / Q000556:secondary; D014859:Warfarin / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D014859:Warfarin; D003520:Cyclophosphamide